Apollomics, Inc. (APLM)
APLMNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$18.60
+0.3500 (+1.92%) today
At the close, Nov 10, 4:00 PM ET. After hours $18.69 –
- Market cap
- $54.13m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $17.70 to $20.10
- 52-week range
- $12.58 to $28.29
- Average volume
- 12.2k
- Previous close
- $18.25
Earnings
Next report
Financials
No quarterly figures from the source.
News
8 latest- Apollomics CEO Buys Over $7.55 Million In Shares; Shares Rally RTTNews · Aug 18, 2026
- After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day RTTNews · Aug 17, 2026
- Apollomics Announces $10 Million Private Placement; Stock Down RTTNews · Aug 12, 2026
- Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch RTTNews · Jul 16, 2026
- Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data RTTNews · Jul 15, 2026
- Apollomics Receives Nasdaq Deficiency Notice, Reclaims Asian Rights To Vebreltinib; Stock Up RTTNews · Jun 25, 2026
- Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA RTTNews · Jun 22, 2026
- Apollomics Secures $2 Million Bridge Financing To Support Clinical Programs RTTNews · Apr 1, 2026
The company
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics' lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- apollomicsinc.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.